Retinoid X Receptor Ligands with Anti-Type 2 Diabetic Activity

Related Experiment Video

Updated: Mar 19, 2026

Author Spotlight: Understanding Retinal Vessel Resilience and Disease Progression
04:36

Author Spotlight: Understanding Retinal Vessel Resilience and Disease Progression

Published on: January 12, 2024

1.7K

Ken-Ichi Morishita, Hiroki Kakuta1

  • 1Division of Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 1-1-1 Tsushima-Naka, Kita-ku, Okayama 700- 8530, Japan.

Current Topics in Medicinal Chemistry
|June 21, 2016
PubMed

Insights

Retinoid X receptor (RXR) agonists and antagonists show potential for treating type 2 diabetes by modulating peroxisome proliferator-activated receptor gamma (PPARγ) activity. RXR partial agonists offer a promising approach with reduced side effects.

Area of Science:

  • Endocrinology
  • Molecular Biology
  • Pharmacology

Background:

  • Peroxisome proliferator-activated receptor gamma (PPARγ) regulates glucose metabolism and is a target for type 2 diabetes treatment.
  • PPARγ functions via heterodimers with retinoid X receptors (RXRs).
  • Both PPARγ and RXR agonists can activate these heterodimers, influencing anti-diabetic effects.

Purpose of the Study:

  • To review RXR agonists, antagonists, and modulators for their anti-diabetic effects.
  • To discuss the therapeutic potential and suitability of RXR-targeting agents in type 2 diabetes management.
  • To highlight the role of RXR modulators in mitigating side effects associated with full RXR agonists.

Main Methods:

  • Literature review of studies on RXR agonists, antagonists, and partial agonists.
  • Analysis of reported anti-diabetic effects and associated side effect profiles.
  • Evaluation of the mechanism of action involving RXR/PPARγ heterodimers.

Main Results:

  • RXR agonists, antagonists, and partial agonists demonstrate therapeutic potential in type 2 diabetes.
  • Full RXR agonists are associated with side effects like triglyceride elevation and hypothyroidism.
  • RXR partial agonists (modulators) show promise for reduced side effects while maintaining anti-diabetic efficacy.

Conclusions:

  • RXR modulators represent a promising class of agents for type 2 diabetes treatment due to their efficacy and improved side effect profile.
  • Further investigation into RXR antagonists and modulators is warranted for developing novel anti-diabetic therapies.
  • Targeting RXR/PPARγ heterodimers offers a versatile strategy for managing type 2 diabetes.

More Related Videos

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes16:26

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

6.3K
Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells07:22

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells

Published on: March 28, 2013

39.6K

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.2K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
871
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
934
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
879
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.4K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
808